4697-57-8

Basic information

• Product Name: methyl 2-(2-bromo-4,5-dimethoxyphenyl)acetate
• Synonyms: methyl 2-(2-bromo-4,5-dimethoxyphenyl)acetate
• CAS NO: 4697-57-8
• Molecular Weight: 289.126
• Mol File: 4697-57-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 66 °C
• Boiling Point: 330.9±37.0 °C(Predicted)
• Density: 1.400±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl 2-(2-bromo-4,5-dimethoxyphenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(2-bromo-4,5-dimethoxyphenyl)acetate(4697-57-8)
• EPA Substance Registry System: methyl 2-(2-bromo-4,5-dimethoxyphenyl)acetate(4697-57-8)

Safety Data

• Hazardous Substances Data: 4697-57-8(Hazardous Substances Data)

Upstream product

• 15964-79-1 methyl (3,4-dimethoxyphenyl)acetate 
• 51655-39-1 2-bromo-4,5-dimethoxyphenylacetonitrile 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 67-56-1 methanol 
• 4697-62-5 6-bromohomoveratric acid 

Downstream Products

• 1107040-14-1 methyl 2-(2-bromo-4,5-dimethoxyphenyl)propanoate 
• 1386350-95-3 C₁₃H₁₇BrO₃ 
• 1386350-92-0 1-(1-(benzyloxy)pent-4-en-2-yl)-2-bromo-4,5-dimethoxybenzene 
• 1386351-89-8 C₁₉H₂₁BrO₄ 
• 1386350-97-5 4-(benzyloxy)-3-(2-bromo-4,5-dimethoxyphenyl)butan-1-ol 
• 1386350-99-7 4-(benzyloxymethyl)-6,7-dimethoxychroman 
• 70666-01-2 methyl α-bromo-(2-bromo-4,5-dimethoxyphenyl)acetate 
• 52358-58-4 (+)-erysotramidine 
• 1386350-91-9 methyl 2-(2-bromo-4,5-dimethoxyphenyl)pent-4-enoate 
• 118671-32-2 methyl 1-benzyl-5,6-dimethoxy-2-methyl-1H-indole-3-carboxylate 

Relevant articles and documents

Lead Optimization: Synthesis and Biological Evaluation of PBT-1 Derivatives as Novel Antitumor Agents

Phenanthrene-based tylophorine-1 (PBT-1) was identified previously as a lead compound in an anticancer drug discovery effort based on natural Tylophora alkaloids. An expanded structural optimization using a new more efficient synthetic route provided 14 P

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound inhibiting Hsp 90 and to a pharmaceutical composition including same as an active ingredient. Compounds of formula 1 and formula 2 according to the present invention inhibit the accumulation of HIF-1α protein, which is an Hsp90 client protein, by suppressing Hsp90 expression, and effectively inhibit the activity of vascular endothelial growth factor (VEGF). Furthermore, said compounds have low cytotoxicity and can thus be used as an active ingredient for the treatment of diabetic retinopathy and arthritis.

Facile synthesis of 4,5,6a,7-tetrahydrodibenzo[de,g]chromene heterocycles and their transformation to phenanthrene alkaloids

Oxa-Pictet-Spengler cyclization and microwave-assisted C-H arylation have been implemented as key steps in the synthesis of new isochroman heterocycles containing a 4,5,6a,7-tetrahydrodibenzo[de,g]chromene motif. These isochromans may be easily transformed to phenanthrene alkaloids via acidic cleavage of the isochroman ring and standard synthetic manipulations thereafter. The route described is attractive in that it provides access to two biologically interesting scaffolds in simple and high yielding synthetic steps.